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Use of blood pressure lowering drugs in the prevention of
cardiovascular disease: meta-analysis of 147 randomised
trials in the context of expectations from prospective
epidemiological studies
M R Law, professor of epidemiology J K Morris, professor of medical statistics N J Wald, professor of
environmental and preventive medicine
ABSTRACT
Objectives To determine the quantitative efficacy of
different classes of blood pressure lowering drugs in
preventing coronary heart disease (CHD) and stroke, and
who should receive treatment.
Design Meta-analysis.
Data source Medline (1966-2007).
Study selection Randomised trials of blood pressure
lowering drugs recording CHD events and strokes. 108
trials studied differences in blood pressure between
studydrugandplacebo(orcontrolgroupnotreceivingthe
study drug) (“blood pressure difference trials”), and 46
trials compared drugs (“drug comparison trials”). Seven
trials with three randomised groups fell into both
categories. The results were interpreted in the context of
those expected from the largest published meta-analysis
of cohort studies, totalling 958000 people.
Participants 464000 people defined into three mutually
exclusive categories: participants with no history of
vascular disease, a history of CHD, or a history of stroke.
Results In the blood pressure difference trials β blockers
had a special effect over and above that due to blood
pressure reduction in preventing recurrent CHD events in
people with a history of CHD: risk reduction 29% (95%
confidence interval 22% to 34%) compared with 15%
(11% to 19%) in trials of other drugs. The extra effect was
limited to a few years after myocardial infarction, with a
risk reduction of 31% compared with 13% in people with
CHD with no recent infarct (P=0.04). In the other blood
pressure difference trials (excluding CHD events in trials
of β blockers in people with CHD), there was a 22%
reductioninCHDevents(17%to27%)anda41%(33%to
48%)reductioninstrokeforabloodpressurereductionof
10 mm Hg systolic or 5 mm Hg diastolic, similar to the
reductions of 25% (CHD) and 36% (stroke) expected for
the same difference in blood pressure from the cohort
study meta-analysis, indicating that the benefit is
explained by blood pressure reduction itself. The five
mainclassesofbloodpressureloweringdrugs(thiazides,
β blockers, angiotensin converting enzyme inhibitors,
angiotensin receptor blockers, and calcium channel
blockers)weresimilarlyeffective(withinafewpercentage
points) in preventing CHD events and strokes, with the
exception that calcium channel blockers had a greater
preventive effect on stroke (relative risk 0.92, 95%
confidence interval 0.85 to 0.98). The percentage
reductions in CHD events and stroke were similar in
people with and without cardiovascular disease and
regardless of blood pressure before treatment (down to
110 mm Hg systolic and 70 mm Hg diastolic). Combining
our results with those from two other studies (the meta-
analyses of blood pressure cohort studies and of trials
determining the blood pressure lowering effects of drugs
accordingtodose)showedthatinpeopleaged60-69with
a diastolic blood pressure before treatment of 90 mm Hg,
threedrugsathalfstandarddoseincombinationreduced
the risk of CHD by an estimated 46% and of stroke by
62%; one drug at standard dose had about half this
effect. The present meta-analysis also showed that drugs
other than calcium channel blockers (with the exception
of non-cardioselective β blockers) reduced the incidence
ofheartfailureby24%(19%to28%)andcalciumchannel
blockers by 19% (6% to 31%).
Conclusions With the exception of the extra protective
effect of β blockers given shortly after a myocardial
infarction and the minor additional effect of calcium
channel blockers in preventing stroke, all the classes of
blood pressure lowering drugs have a similar effect in
reducing CHD events and stroke for a given reduction in
blood pressure so excluding material pleiotropic effects.
The proportional reduction in cardiovascular disease
eventswasthesameorsimilarregardlessofpretreatment
blood pressure and the presence or absence of existing
cardiovascular disease. Guidelines on the use of blood
pressure lowering drugs can be simplified so that drugs
areofferedtopeoplewithalllevelsofbloodpressure.Our
results indicate the importance of lowering blood
pressure in everyone over a certain age, rather than
measuring it in everyone and treating it in some.
INTRODUCTION
Despite the widespread use of blood pressure lowering
drugs and the results of many randomised trials,
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who to treat. Five questions encapsulate this uncer-
t a i n t y .F i r s t l y ,d oβ blockers have a special effect over
and above lowering blood pressure in preventing cor-
onary heart disease (CHD) events in people with a his-
toryofCHD?Thisviewiswidelyheldbutsuchaneffect
hasnotbeenshowndirectlyorquantified.Weaimedto
answer this question from an analysis of all relevant
trials, and then to answer four further questions after
excluding CHD events in trials of β blockers in people
with a history of CHD if they did have a special effect.
Secondly, does the effect of blood pressure lowering
drugs in preventing CHD and stroke differ in people
with and without a history of cardiovascular disease
(that is, is there a different effect in secondary and pri-
mary prevention)? Thirdly, does blood pressure reduc-
tionalone explain the effect of blood pressure lowering
drugs inpreventing CHD andstroke?There are claims
of additional non-blood pressure lowering (so called
pleiotropic) effects of drugs.
7813w135 w136 w139 Selected
trial data have been used to suggest that each of the
fivemainclassesofbloodpressureloweringdrugs(thia-
zides, β blockers, angiotensin converting enzyme inhi-
bitors, angiotensin receptor blockers, and calcium
channel blockers) has a greater preventive effect,
1-13
w126 w129 and each a lesser preventive effect,
9-20w126 w135
than other drugs. Clinical guidelines tend to reflect the
view that differences in efficacy exist.
21-23 Fourthly,
shouldtheuse ofbloodpressureloweringdrugsbelim-
itedtopeoplewith“high”bloodpressureandnotgiven
tothose athigh risk ofcardiovasculardiseasewhohave
a lower blood pressure? A corollary is whether blood
pressure should be reduced to a limited extent only, a
treat to target approach.
9-1121-24 Although cohort (pro-
spective observational) studies do not show a lower
blood pressure limit below which risk ceases to decline
(“the lower the better”),
25-27 this has not been shown in
randomisedtrialsacrossawiderangeofbloodpressure.
Finally, what is the quantitative effect of taking one or
more blood pressure lowering drugs in lowering blood
pressure and preventing CHD events and stroke
according to dose, pretreatment blood pressure, and
age? To date no such quantitative summary of effect,
taking account of these determining factors, has been
made.
We answered these questions using the results from
147 randomised trials of blood pressure lowering
drugs and CHD events (n=22000) and stroke (n=
12000), examined in the context of the results from
thelargestmeta-analysisofepidemiologicalcohortstu-
diesofbloodpressureandCHDandstroke.
25Previous
meta-analyses of randomised trials of blood pressure
lowering drugs and cardiovascular disease included
fewer than 40 trials.
1-2028 We also quantified the effect
of blood pressure lowering drugs on the incidence of
heartfailureandoncancermortality,othernon-vascu-
lar mortality, and all cause mortality.
METHODS
The database search (by MRL) used Medline (1966 to
December2007;anylanguage)toidentifyrandomised
trials of blood pressure lowering drugs in which CHD
events or strokes were recorded (irrespective of
whether blood pressure reduction was considered the
mechanism of action). Search terms were “anti-hyper-
tensive agents” or “hypertension” or “diuretics,
thiazide” or “adrenergic beta-antagonists” or “angio-
tensin-converting enzyme inhibitors” or “receptors,
angiotensin/antagonists & inhibitors” or “tetrazoles”
or “calcium channel blockers” or “vasodilator agents”
orthenamesofallbloodpressureloweringdrugslisted
in the British National Formulary as keywords or text
words. Limits were Medline publication type “clinical
trial”or“controlledclinicaltrial”or “randomizedcon-
trolled trial” or “meta-analysis”. We also searched the
Cochrane Collaboration and Web of Science data-
bases and the citations in trials and previousmeta-ana-
lysis and review articles.
Trials of β blockers
  People with history of coronary heart disease
  Entry after acute myocardial infarction
  Entry after long term coronary heart disease
  People with no history of coronary heart disease
Trials of drugs other than β blockers
  People with history of coronary heart disease
  People with no history of coronary heart disease
All trials except ones of β blockers in people
0.71 (0.66 to 0.78)
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Fig 1 | Relative risk estimates of coronary heart disease events in single drug blood pressure difference trials according to drug
(β blockers or other), presence of CHD, and for β blockers according to acute myocardial infarction on entry. (Totals are less
than the sum of the individual categories because some trials include more than one category; see web extra figures 1a-e for
individual trial results and summary estimates)
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which treated groups but not control groups had
otherinterventionsaswellasbloodpressurereduction,
such as cholesterol reduction. We excluded trials in
patients with chronic renal failure because these
patients typically have high blood pressure and high
rates of cardiovascular disease and their response to
standard blood pressure lowering therapy may differ
from other people. We also excluded trials in which
fewerthanfiveCHDeventsandstrokeswererecorded
or the duration of treatment was less than six months,
as these data would contribute little to the overall
results and substantially increase the complexity of
the analyses. Randomised trials were otherwise
included irrespective of participants’ age, disease sta-
tus, blood pressure before treatment, or use of other
drugs.
Data extraction
We recorded the numbers of participants having one
ormoreCHDevents(definedasfatalornon-fatalmyo-
cardial infarction or sudden cardiac death but exclud-
ing “silent” infarcts) and one or more strokes
(haemorrhagic and ischaemicstrokes could not be dis-
tinguished). We also recorded the numbers of partici-
pants with a new diagnosis of heart failure or an
exacerbation of existing heart failure based on new
hospital admissions or death from the disorder. Two
authors (MRL and NJW) independently recorded
data, with differences resolved by discussion. Out-
comes were recorded regardless of whether partici-
pants took their allocated tablets (intention to treat
analysis). Change in blood pressure in the trials
(value on entry minus the average value during the
trial in the treated group, minus the same change in
the control group) was recorded on an intention to
treat basis by determining the numbers of participants
in the treated and in the control groups who stopped
attending the clinics (so that their blood pressure
reduction was no longer recorded) and taking the dif-
ferenceinbloodpressurebetweenthemtobezeroafter
they left the trial.
Categories of trial
The trials were divided into three predefined cate-
gories according to whether the recruitment was
based on participants having no history of cardio-
vascular disease, a history of CHD (acute myocardial
infarction, coronary artery disease without recent
infarction, or heart failure), or a history of stroke (or
other cerebrovascular disease). In the trials of partici-
pants with no history of vascular disease, blood pres-
sure was usually high, variably defined, and a treat to
target approach was used, typically based on one drug
with the dose increased before the addition of other
drugs to reach the target blood pressure. The control
groupswereallocatedtousualcare.Inthetrialsofpar-
ticipants with a history of CHD therewas generally no
selection by blood pressure and no blood pressure tar-
get; treated patients were allocated a specified drug in
fixed dose, varied only to avoid adverse effects. In the
trials of participants with a history of stroke most fol-
lowed the treat to target approach, some followed the
specified drug approach. In trials of participants who
had acute myocardial infarction on entry sudden
deaths while in hospital were not recorded because it
wasnot our objectiveto assessthe efficacy ofthe drugs
in reducing mortality in the period immediately after
infarction; the CHD events and heart failure episodes
we recorded were either those designated as reinfarc-
tion or those occurring after hospital discharge. Simi-
larly in trials of participants who had heart failure on
entry, sudden deaths were not recorded (as ischaemia
and worseningheartfailure could not bedistinguished
as causes). In trials of participants with CHD and who
had acute myocardial infarction or heart failure on
entry,
2930 many of the strokes recorded were likely to
have been embolic (thrombus formation on an acute
infarct or in a dilated left ventricle) and therefore not
preventable by blood pressure reduction, so the esti-
mateofthereductioninstrokewastakenfromthetrials
inwhichparticipantshadcoronaryarterydiseasewith-
out recent infarction or heart failure.
We also categorised the trials into “blood pressure
differencetrials”and“drugcomparisontrials.”(Details
of each trial are given in web extra tables 1i-iii and 2.)
The blood pressure difference trials were those
designed to achieve a difference in blood pressure
between randomised groups who were given and
were not given the study drugs to show the effect of
this difference on the incidence of CHD events and
stroke. Ninety two of the 108 trials in this category
were placebo controlled, but in 16 the control group
was not given a placebo. Additional blood pressure
lowering drugs were commonly used in the different
groups in each trial—for example, in trials comparing
an angiotensin converting enzyme inhibitor with pla-
cebo in people with CHD, participants in both groups
might also receive β blockers or calcium channel
blockers, whereas in trials in which a treat to target
approach was used, add-on drugs were given if neces-
sary in both actively treated and placebo treated parti-
cipants to reach their blood pressure targets (the target
being lower for treated participants than for placebo
participants). Through their design the blood pressure
difference trials ensured that the intervention groups
were more intensively treated. Trials were regarded
assingledrugtrialsifthedifferencebetweenthegroups
in the mean number of drugs prescribed per partici-
pant (study drug included) was less than 1.5 (in the
event 1.0 on average, and as combination drug trials
ifthemeannumberofdrugsprescribedperparticipant
was 1.5 or greater (2.0 on average).
Drug comparison trials were those that compared
two blood pressure lowering drugs with each other.
Although additional drugs could be used in either
group there was no intention to achieve a different
blood pressure reduction in one group compared
with another. These trials therefore tested for effects
of a drug that were unrelated to lowering blood pres-
sure. In two drug comparison trials of three drugs
w129
w147 each of the three pairwise comparisons was
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drugs of a class allocated to one randomised group
could not be used in the other.
Statistical analysis
All statistical analyses were done using Stata software.
We combined relative risk estimates of disease events
from individual trials using a random effects model
31
(which avoids assuming that participants in the indivi-
dualtrialsinthemeta-analysisaresampledfrompopu-
lations in which the intervention has the same
quantitative effect). Summary relative risk estimates
from blood pressure difference trials were standar-
dised to a blood pressure reduction of 10 mm Hg sys-
tolic or 5 mm Hg diastolic, by raising the relative risk
estimate in each trial to the appropriate power (10
divided by the observed reduction in systolic blood
pressureor5dividedbytheobservedreductionindia-
stolic pressure)—for example, if the relative risk was
0.7 and the reduction in systolic blood pressure was
8 mm Hg, the standardised relative risk estimate was
0.64(0.7
1.25,since10/8=1.25).Ifreductionsinbothsys-
tolic and diastolic blood pressureswere reported (as in
most trials), we took the average of the two risk esti-
mates (more strongly predictive than either alone
25).
As the reduction in blood pressure was not reported
in most trials of people with a history of CHD, we esti-
mated the average reduction from the average blood
pressure before treatment and the average drug dose
(asamultipleofstandarddose
3233),usingresultsfroma
meta-analysisinwhichtheeffectofpretreatmentblood
pressure and dose on blood pressure reduction was
quantified.
32 The estimated blood pressure reduction
was 5.9 mm Hg systolic and 3.1 mm Hg diastolic,
Table 1 |Randomised trials of blood pressure lowering drugs according to category of trial (see web extra tables 1i-iii and 2 for details of individual trials)
Trial category and clinical history of
participants on entry Nooftrials
No of
partici-
pants
Mean age
on entry
(years)
Mean
duration
(years)
No of disease events recorded
Range of mean pretreatment blood
pressureinindividualtrials(mmHg)
Coronary
heart
disease Stroke
Heart
failure Systolic Diastolic
Blood pressure difference trials
No vascular disease*
w1-w33 27 108 297 62 4.5 3429 2843 582 132-186 72-119
Coronary heart disease†:
Trials of β blockers
w34-w72 37 38 892 57 1.7 2524 20 3198 112-149 72-92
Trials of other drugs
w73-w112 37 85 395 62 3.6 5815 964 6831 113-141 70-86
Stroke‡
w1 w7 w9 w29 w30 w113-w121 13* 16 085 64 3.1 567 1593 13 132-186 72-115
All blood pressure difference trials
w1-w121 108 248 445 62 3.5 12 324 5420 10 624 112-186 70-119
Drug comparison trials
Alltrialcategories¶
w13-w17 w26 w34 w82 w122-w162 46 230 491 67 4.5 10 357 6862 7317 123-194 71-108
All trials 147§ 464 164§ 64 4.0 22 115§ 12 034§ 17 890§ 112-194 70-119
*In the event 3% of participants had a history of myocardial infarction and 3% of stroke.
†In the event 90% of participants had a proved coronary heart disease, 8% had heart failure not caused by coronary heart disease, 1% had peripheral arterial or cerebrovascular disease,
and 1% had no known vascular disease.
‡All participants had stroke or other cerebrovascular disease.
§“All trials” totals are less than column totals because six trials with two randomised treatment groups and one placebo group, included both as blood pressure difference trials and drug
comparison trials,
w11-w14 w29 w82 are counted twice; a seventh such trial is counted three times; and participants in five trials of stroke on entry were subgroups in five predominantly “no
vascular disease” trials
w5 (see web extra table 1iii).
¶Participants had no vascular disease in most drug comparison trials; see web extra table 2.
  No history of vascular disease
  History of coronary heart disease
  History of stroke
  All trials
Cohort studies
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Fig 2 | Relative risk estimates of coronary heart disease events and stroke for a blood pressure reduction of 10 mm Hg systolic or 5 mm Hg diastolic in the
blood pressure difference trials and in epidemiological cohort studies. (Total number of trials is fewer than the sum of the three categories as five included
participants with and without vascular disease; see web extra figures 2a-f for individual trial results and summary estimates)
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blood pressure reduction was reported, which was
6 mm Hg systolic and 3 mm Hg diastolic.
Predicting the trial results on CHD and stroke from
epidemiological studies and trials of drugs on blood
pressure
Effect of blood pressure lowering drugs in lowering blood
pressure according to dose
These estimates are taken from a meta-analysis of 354
short term randomised placebo controlled trials of
blood pressure lowering drugs in fixed dose,
32 which
showedthatthefivemainclassesofbloodpressurelow-
ering drugs produce similar reductions in blood pres-
sure when taken at standard dose or at the same
multiple of standard dose. It also showed that the
blood pressure lowering effect of the drugs increased
with dose and with pretreatment blood pressure, and
reportedregressionequationsthatquantifiedthereduc-
tion in blood pressure from one drug according to pre-
treatment blood pressure. From the average blood
pressureof154mmHgsystolicand97mmHgdiastolic
one drug at standard dose lowered blood pressure by
9.1mmHgsystolicand5.5mmHgdiastoliconaverage.
At lower or higher pretreatment blood pressures the
blood pressure reduction decreased (or increased) by
0.10 mm Hg systolic and 0.11 mm Hg diastolic per
mm Hg decrease (or increase) in pretreatment blood
pressure. The estimated effect of one drug at standard
dose in lowering blood pressure from a pretreatment
bloodpressurePistherefore[9.1+0.10(P−154)]systolic
and [5.5+0.11(P−97)] diastolic. So for example the
reduction in blood pressure was 8.7 mm Hg systolic
from a pretreatment value of 150 mm Hg, 4.7 mm Hg
diastolic from a pretreatment value of 90 mm Hg. The
estimated blood pressure reduction for two or three
drugs at standard dose was calculated by applying
these equations to each drug in turn, allowing for the
effect of the first in lowering pretreatment blood pres-
sure for the second, and the second for the third. In the
aboveexample the pretreatment bloodpressure for the
second drug would be 141.3 (150−8.7) mm Hg systolic
and 85.3 (90−4.7) mm Hg diastolic.
Using drugs at half standard dose, taking dose and
pretreatment blood pressure into account, it was esti-
mated in the meta-analysis of 354 trials that one, two,
and three drugs at half standard dose reduced a pre-
treatment systolic pressure of 150 mm Hg by 6.7 mm
Table 2 |Summary relative risk estimates (95% confidence intervals) for coronary heart disease (CHD) events and stroke
from randomised blood pressure difference trials observed and standardised to a blood pressure reduction of 10 mm Hg
systolic and 5 mm Hg diastolic
Clinical history of
participants on entry No of trials
Observed
Standardised for blood pressure
reduction
CHD events Stroke CHD events Stroke
No vascular disease 27 0.84 (0.79 to 0.90) 0.64 (0.56 to 0.73) 0.79 (0.72 to 0.86) 0.54 (0.45 to 0.65)
CHD* 37 0.85 (0.79 to 0.91) 0.77 (0.68 to 0.87) 0.76 (0.68 to 0.86) 0.65 (0.53 to 0.80)
Stroke 13† 0.85 (0.73 to 1.00) 0.76 (0.68 to 0.85) 0.79 (0.62 to 1.00) 0.66 (0.56 to 0.79)
All trials* 72 0.84 (0.81 to 0.88) 0.70 (0.65 to 0.76) 0.78 (0.73 to 0.83) 0.59 (0.52 to 0.67)
*Summary estimates omitting CHD events (but not strokes) in trials of β blockers in patients with a clinical history of CHD (heterogeneity for CHD,
χ
2=0.02, df=2, P=0.99; heterogeneity for stroke, χ
2=2.0, df=2, P=0.37).
†Includes subgroups of participants with stroke on entry from five predominantly “no vascular disease” trials so total is less than the sum of the
individual categories
w5 (see web extra table 1iii).
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β blockers
Angiotensin converting enzyme inhibitors
Angiotensin receptor blockers
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Drug choice open
All classes of drug
0.86 (0.75 to 0.98)
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0.62 (0.53 to 0.72)
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Fig 3 | Relative risk estimates of coronary heart disease events and stroke in single drug blood pressure difference trials according to class of drug (excluding
CHD events in trials of β blockers in people with history of coronary heart disease). (Totals are less than the sum of the individual categories because some
trials include more than one category; see web extra figures 3a-i for individual trial results and summary estimates)
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reducedapretreatmentdiastolicpressureof90mmHg
by 3.7 mm Hg, 7.3 mm Hg, and 10.7 mm Hg, respec-
tively (allowing for the effect of one drug in lowering
pretreatment blood pressure for the next; table 4).
32
These blood pressure reductions decreased (or
increased) by an estimated 0.078 mm Hg systolic and
0.088 mm Hg diastolic, per mm Hg decrease (or
increase) in pretreatment blood pressure per drug,
22% and 20% lower, respectively, than the changes at
standard dose (0.10 mm Hg and 0.11 mm Hg.
32 The
blood pressure reductions from one, two, and three
drugs at half standard dose were [R+n×0.078(P−150)]
systolic and [R+n×0.088(P−90)] diastolic, where R is
the blood pressure reduction at 150 mm Hg systolic
or 90 mm Hg diastolic (given above), n is the number
of drugs, and P is the pretreatment blood pressure
Expected reduction in disease events for a specified
reduction in blood pressure
The associations between systolic and diastolic blood
pressure and CHD events and stroke were taken from
the largest published meta-analysis of 61 cohort (pro-
spective observational) studies.
25 This showed that in
every age group cardiovascular mortality plotted on a
logarithmic scale against blood pressure on an arith-
metic scale is well fitted by straight lines, indicating a
constant proportional change in risk for a specified
change in blood pressure from any level of pretreat-
ment blood pressure. Age specific slopes of the lines
(regression coefficients) were published, permitting
thecalculationofthepredictedproportionalreduction
indiseaseeventsforanyageandbloodpressurediffer-
ence. For an age specific regression slope, S (see web
extra table 3), and decrease in blood pressure, d, the
relative risk is S
d/20 for systolic pressure and S
d/10 for
diastolic pressure. The following examples illustrate
thecalculations.Atage60-69,therelativeriskofstroke
is 0.43 (57% decrease) for a 20 mm Hg decrease in sys-
tolic blood pressure. For a blood pressure decrease
twice as great (40 mm Hg), the relative risk of 0.43
effectively applies twice (0.43×0.43, or 0.43
2), which
is 0.18 (an 82% decrease). For a reduction in blood
pressure half as great, by symmetry the relative risk is
√0.43, or 0.43
1/2, which is 0.66 (a 34% decrease). For a
30 mm Hg decrease in blood pressure the relative risk
is 0.43
1.5 (since 30/20=1.5), which is 0.28 (a 72%
decrease). Thesloping lines in the lower portion of fig-
ure6reflecttheseregressioncoefficientsforstrokeand
CHD events in the age groups 50-59, 60-69, and
70-79 years.
The effect of blood pressure lowering drugs in redu-
cingtheriskofCHDeventsandstrokecanthereforebe
estimated according to the reduction in systolic or dia-
stolic blood pressure (or the average of the two), from
the regressionslope,S, andthe decrease inbloodpres-
sure, d, from the above equations. As an example, the
effectofthreedrugsathalfstandarddoseinpreventing
stroke in people aged 60-69 with a pretreatment systo-
lic blood pressure of 180 mm Hg systolic is estimated
as: decrease in systolic blood pressure=[19.9
+(3×0.078×(180−150))]=26.9 mm Hg, and relative
risk of stroke=0.43
26.9/20=0.32 (a 68% decrease).
RESULTS
Overall,147trialreportswereincludedintheanalysis:
108 were blood pressure difference trials and 46 drug
comparison trials (seven trial reports with two treat-
ment groups and a placebo group fell into both cate-
gories, treatment versus placebo and one treatment
versus the other). Table 1 summarises the trials (see
web extra tables 1i-iii and 2 for individual data from
thetrials).Forestplotsofindividualtrialresultsarepre-
sented in 55 web extra figures (available at www.wolf
son.qmul.ac.uk/bptrial/) and the summary relative
risk estimates and results for heterogeneity testing are
shown in web extra table A. Results on CHD events
and stroke are presented first, according to the five
questions posed in the introduction, followed by
results on heart failure and all cause mortality.
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Fig 4 | Relative risk estimates of coronary heart disease events and stroke in 46 drug comparison trials comparing each of the five classes of blood pressure
lowering drug with any other class of drug (excluding CHD events in trials of β blockers in people with a history of coronary heart disease; see web extra
figures 4a-j for individual trial results and summary estimates)
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page 6 of 19 BMJ | ONLINE FIRST | bmj.comTable 3 |Estimates of preventive effect of taking one or more blood pressure lowering drugs on coronary heart disease (CHD) events and stroke according to
pretreatment systolic blood pressure, age, number of drugs, and dose (as multiple of standard
33)
Pretreatment systolic blood
pressure (mm Hg)
Estimated reduction
in systolic blood
pressure (mm Hg)*
Relative risk of CHD events by age (years) Relative risk of stroke by age (years)
40-49 50-59 60-69 70-79 80-89 40-49 50-59 60-69 70-79 80-89
One drug half standard dose:
180 9.0 0.72 0.73 0.76 0.79 0.83 0.63 0.65 0.68 0.73 0.83
170 8.3 0.74 0.75 0.78 0.81 0.85 0.66 0.67 0.71 0.75 0.85
160 7.5 0.77 0.77 0.79 0.83 0.86 0.68 0.70 0.73 0.77 0.86
150 6.7 0.79 0.79 0.81 0.84 0.87 0.71 0.72 0.75 0.79 0.87
140 5.9 0.81 0.81 0.83 0.86 0.89 0.74 0.75 0.78 0.81 0.89
130 5.1 0.83 0.84 0.85 0.88 0.90 0.77 0.78 0.81 0.84 0.90
120 4.4 0.86 0.86 0.87 0.89 0.92 0.80 0.81 0.83 0.86 0.92
One drug standard dose:
180 11.7 0.66 0.67 0.70 0.74 0.79 0.55 0.57 0.61 0.67 0.79
170 10.7 0.68 0.69 0.72 0.76 0.81 0.58 0.60 0.64 0.69 0.81
160 9.7 0.71 0.71 0.74 0.78 0.82 0.61 0.63 0.66 0.71 0.82
150 8.7 0.73 0.74 0.76 0.80 0.84 0.64 0.66 0.69 0.74 0.84
140 7.7 0.76 0.77 0.79 0.82 0.86 0.67 0.69 0.72 0.77 0.86
130 6.7 0.79 0.79 0.81 0.84 0.87 0.71 0.72 0.75 0.79 0.87
120 5.7 0.82 0.82 0.84 0.86 0.89 0.75 0.76 0.79 0.82 0.89
Two drugs half standard dose:
180 18.0 0.53 0.54 0.57 0.63 0.70 0.40 0.42 0.47 0.54 0.70
170 16.4 0.56 0.57 0.60 0.66 0.72 0.43 0.45 0.50 0.57 0.72
160 14.5 0.59 0.60 0.63 0.68 0.74 0.47 0.49 0.53 0.60 0.74
150 13.3 0.62 0.63 0.66 0.71 0.77 0.51 0.53 0.57 0.63 0.77
140 11.7 0.66 0.67 0.70 0.74 0.79 0.55 0.57 0.61 0.67 0.79
130 10.2 0.70 0.70 0.73 0.77 0.82 0.59 0.61 0.65 0.70 0.82
120 8.6 0.74 0.74 0.77 0.80 0.84 0.64 0.66 0.70 0.74 0.84
Two drugs standard dose:
180 22.2 0.45 0.46 0.50 0.57 0.64 0.32 0.34 0.39 0.46 0.64
170 20.3 0.48 0.49 0.53 0.59 0.67 0.35 0.37 0.42 0.47 0.67
160 18.4 0.52 0.53 0.57 0.62 0.69 0.39 0.41 0.46 0.53 0.69
150 16.5 0.55 0.56 0.60 0.66 0.72 0.43 0.45 0.50 0.56 0.72
140 14.6 0.59 0.60 0.64 0.69 0.75 0.47 0.49 0.54 0.60 0.75
130 12.7 0.64 0.64 0.68 0.72 0.77 0.52 0.54 0.58 0.64 0.77
120 10.8 0.68 0.69 0.72 0.76 0.81 0.58 0.59 0.63 0.69 0.81
Three drugs half standard dose:
180 26.9 0.38 0.39 0.44 0.50 0.58 0.25 0.27 0.32 0.39 0.58
170 24.6 0.42 0.43 0.47 0.53 0.61 0.28 0.30 0.35 0.43 0.61
160 22.2 0.45 0.46 0.50 0.57 0.64 0.32 0.34 0.39 0.46 0.64
150 19.9 0.49 0.50 0.54 0.60 0.67 0.36 0.38 0.43 0.50 0.67
140 17.6 0.50 0.51 0.55 0.61 0.68 0.37 0.39 0.44 0.54 0.68
130 15.2 0.58 0.59 0.63 0.68 0.74 0.46 0.48 0.53 0.59 0.74
120 12.9 0.63 0.64 0.67 0.72 0.77 0.52 0.54 0.58 0.64 0.77
Three drugs standard dose:
180 31.7 0.32 0.33 0.38 0.44 0.53 0.20 0.22 0.26 0.33 0.53
170 29.0 0.36 0.37 0.41 0.48 0.56 0.23 0.25 0.29 0.37 0.56
160 26.3 0.39 0.40 0.44 0.51 0.59 0.26 0.28 0.33 0.40 0.59
150 23.6 0.43 0.44 0.48 0.55 0.62 0.30 0.32 0.37 0.44 0.62
140 20.9 0.48 0.49 0.53 0.59 0.66 0.34 0.36 0.41 0.49 0.66
130 18.2 0.52 0.53 0.57 0.63 0.70 0.40 0.42 0.46 0.53 0.70
120 15.5 0.58 0.59 0.62 0.67 0.73 0.45 0.47 0.52 0.59 0.73
This table is a numerical expansion of figure 7 (systolic blood pressure). Estimates calculated using a two stage procedure in which the effect of drug treatment in reducing systolic blood
pressure was first estimated,
32 then the effect of this blood pressure reduction on disease risk.
25
*See Methods (section headed “Predicting the trial results.”)
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events in people with a history of CHD?
Blood pressure difference trials
Figure 1 shows the reduction in CHD events in the 37
blood pressure difference trials of β blockers in people
witha historyofCHD, comparingβblockerswith pla-
cebo(32trials)orwithanuntreatedcontrolgroup(five
trials). CHD events were, on average, reduced by 29%
(relative risk 0.71, 95% confidence interval 0.66 to
0.78), significantly greater (P<0.001) than the 15%
reduction in single drug trials of β blockers in people
withoutahistoryofCHDandofotherclassesofdrugin
peoplewithandwithoutahistoryofCHD.Thegreater
protectiveeffectofβblockersinpeoplewithCHDwas
explained by a greater effect in the 27 trials that
recruited participants at the time of an acute myo-
cardial infarction (within a month in 25 trials and
within four months in the other two). The risk reduc-
tionforrecurrentCHDeventsinthese27trialsofpeo-
ple with an acute myocardial infarct was 31% (relative
risk 0.69, 0.62 to 0.76); the duration of follow-up was
short (77% of the events occurred in the first year and
94% in the first two years), so almost all the recurrent
events occurred within one or two years of the infarct.
Eleven trials remained (not 10 (37−27) because one
trial recruited some participants with a recent infarct
and some without
w62); these recruited participants
with a history of CHD but no recent infarct and in
these the risk reduction was 13% (relative risk 0.87,
0.71 to 1.06; P=0.04 for the difference between the
two groups of trials). In these 11 trials about 75% of
the participants had had an infarct, but not within the
lastfourmonthsandtypicallyseveralyearsbefore.The
13% risk reduction was similar to the 15% risk reduc-
tions in the other categories of single drug trials,
whereas the 31% risk reduction after acute myocardial
infarction was significantly greater (P<0.001). β block-
ersusedfor oneor twoyearsafter anacute myocardial
infarction were therefore about twice as effective as β
blockers used in other circumstances and about twice
as effective as other drugs used in any circumstances
(see web figures 1a-e for forest plots of the individual
trial results).
Drug comparison trials
The four drug comparison trials of β blockers com-
pared with other drugs in people with CHD but no
recent infarct (see web extra table 2) confirmed the
absence of a special effect of β blockers in the absence
of a recent infarct; the summary relative risk of CHD
eventswas0.99(0.82to1.20),arelativeriskof1.0indi-
cating the same risk reduction from β blockers and
other drugs.
In view of the special effect of β blockers, CHD
events (but not stroke or heart failure) in all 37 blood
pressure difference trials and all four drug comparison
trialsof β blockersin people withCHD were excluded
from subsequent analyses according to the prior
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Fig 5 | Relative risk estimates of coronary heart disease events and stroke in blood pressure difference trials according to pretreatment diastolic and systolic
blood pressures (taken as average in placebo group over course of trial). (Totals are less than the sum of the individual categories because some trialsi n c l u d e
more than one category; see web extra figures 5a-l and 6a-m for individual trial results and summary estimates)
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pretreatment diastolic blood pressure, age, number of drugs, and dose (as multiple of standard
33)
32 then the effect of this blood pressure reduction on
disease risk.
25
Pretreatment diastolic blood
pressure (mm Hg)
Estimated reduction in
diastolic blood pressure
(mm Hg)
Relative risk of CHD events by age (years) Relative risk of stroke by age (years)
40-49 50-59 60-69 70-79 80-89 40-49 50-59 60-69 70-79 80-89
One drug half standard dose:
110 5.5 0.66 0.70 0.73 0.77 0.82 0.56 0.55 0.61 0.67 0.78
105 5 0.68 0.72 0.75 0.79 0.84 0.59 0.58 0.63 0.69 0.79
100 4.6 0.71 0.74 0.77 0.80 0.85 0.62 0.61 0.66 0.71 0.81
95 4.1 0.73 0.76 0.79 0.82 0.86 0.65 0.64 0.68 0.74 0.83
90 3.7 0.76 0.79 0.81 0.84 0.88 0.68 0.67 0.71 0.76 0.84
85 3.3 0.78 0.81 0.83 0.86 0.89 0.71 0.70 0.74 0.79 0.86
80 2.8 0.81 0.83 0.85 0.87 0.90 0.74 0.74 0.77 0.81 0.88
75 2.4 0.84 0.86 0.87 0.89 0.92 0.78 0.77 0.80 0.84 0.90
One drug standard dose:
110 6.9 0.59 0.64 0.67 0.72 0.78 0.48 0.47 0.53 0.60 0.73
105 6.4 0.62 0.66 0.69 0.74 0.80 0.51 0.50 0.56 0.63 0.74
100 5.8 0.64 0.68 0.71 0.76 0.81 0.54 0.53 0.59 0.65 0.76
95 5.3 0.67 0.71 0.74 0.78 0.83 0.57 0.57 0.62 0.68 0.78
90 4.7 0.70 0.73 0.76 0.80 0.84 0.61 0.60 0.65 0.71 0.80
85 4.2 0.73 0.76 0.78 0.82 0.86 0.64 0.64 0.68 0.74 0.82
80 3.6 0.76 0.79 0.81 0.84 0.88 0.68 0.68 0.72 0.77 0.85
75 3.1 0.79 0.82 0.84 0.86 0.90 0.72 0.72 0.75 0.80 0.87
Two drugs half standard dose:
110 10.8 0.44 0.49 0.53 0.60 0.68 0.32 0.31 0.37 0.45 0.61
105 9.9 0.47 0.52 0.56 0.62 0.70 0.35 0.34 0.40 0.48 0.63
100 9.1 0.50 0.55 0.59 0.65 0.72 0.39 0.38 0.44 0.51 0.66
95 8.2 0.54 0.59 0.62 0.68 0.75 0.42 0.41 0.47 0.55 0.69
90 7.3 0.58 0.62 0.65 0.71 0.77 0.46 0.45 0.51 0.59 0.71
85 6.4 0.62 0.66 0.69 0.74 0.80 0.51 0.50 0.56 0.62 0.74
80 5.5 0.66 0.70 0.73 0.77 0.82 0.56 0.55 0.60 0.67 0.77
75 4.7 0.70 0.74 0.76 0.80 0.85 0.61 0.60 0.65 0.71 0.81
Two drugs standard dose:
110 13.1 0.37 0.42 0.49 0.53 0.63 0.25 0.24 0.30 0.38 0.55
105 12.1 0.40 0.45 0.50 0.56 0.65 0.28 0.27 0.33 0.41 0.57
100 11.0 0.44 0.49 0.53 0.59 0.67 0.31 0.30 0.36 0.45 0.60
95 10.0 0.47 0.52 0.56 0.62 0.70 0.35 0.34 0.40 0.48 0.63
90 8.9 0.51 0.56 0.60 0.65 0.73 0.39 0.38 0.44 0.52 0.66
85 7.9 0.55 0.60 0.63 0.69 0.75 0.44 0.43 0.48 0.56 0.69
80 6.9 0.60 0.64 0.67 0.72 0.78 0.49 0.48 0.53 0.60 0.73
75 5.8 0.64 0.68 0.71 0.76 0.81 0.54 0.53 0.59 0.65 0.76
Three drugs half standard dose:
110 16.0 0.30 0.35 0.40 0.47 0.57 0.19 0.18 0.23 0.31 0.48
105 14.7 0.33 0.38 0.43 0.50 0.59 0.21 0.21 0.26 0.34 0.51
100 13.3 0.37 0.42 0.46 0.53 0.62 0.25 0.24 0.29 0.38 0.54
95 12.0 0.40 0.46 0.50 0.56 0.65 0.28 0.27 0.33 0.41 0.57
90 10.7 0.45 0.50 0.54 0.60 0.68 0.33 0.32 0.38 0.46 0.61
85 9.4 0.49 0.54 0.58 0.64 0.72 0.37 0.36 0.42 0.50 0.65
80 8.1 0.54 0.59 0.63 0.68 0.75 0.43 0.42 0.48 0.55 0.69
75 6.7 0.60 0.64 0.68 0.72 0.79 0.49 0.48 0.54 0.61 0.73
Three drugs standard dose:
110 18.6 0.25 0.30 0.34 0.41 0.52 0.14 0.13 0.18 0.26 0.42
105 17.1 0.27 0.33 0.37 0.44 0.54 0.17 0.16 0.21 0.28 0.45
100 15.6 0.31 0.36 0.40 0.47 0.57 0.19 0.19 0.24 0.32 0.49
95 14.2 0.34 0.40 0.44 0.51 0.60 0.23 0.22 0.27 0.35 0.52
90 12.7 0.38 0.44 0.48 0.55 0.64 0.26 0.25 0.31 0.39 0.56
85 11.2 0.43 0.48 0.52 0.59 0.67 0.31 0.30 0.36 0.44 0.60
80 9.7 0.48 0.53 0.57 0.63 0.71 0.36 0.35 0.41 0.49 0.64
75 8.3 0.54 0.58 0.62 0.67 0.74 0.42 0.41 0.47 0.55 0.68
This table is a numerical expansion of figure 6 (diastolic blood pressure). Estimates calculated using a two stage procedure in which the effect of drug treatment in reducing diastolic blood
pressure was first estimated,
32 then the effect of this blood pressure reduction on disease risk.
25
*See Methods (section headed “Predicting the trial results.”)
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observed, even though post hoc the special effect was
limited to a subset (those with acute infarction).
Does the preventive effect of drugs differ in people with
and without a history of cardiovascular disease?
The summary relative risk estimates of CHD events
and stroke in the blood pressure difference trials,
observedandstandardisedforreductioninbloodpres-
sure, were similar in the three categories of trials (no
vascular disease, history of CHD, and history of
stroke), showing no difference in effect in people with
or without vascular disease (table 2, also see web extra
figures 2a-f for forest plots of individual trial results).
There was no heterogeneity across the trials (table 2)
andnospecialeffectofdrugsotherthanβblockersafter
acute myocardial infarction.
Does blood pressure reduction alone explain the
preventive effect of the drugs?
Blood pressure difference trials
Figure 2 shows the relative risk estimates of CHD
events and stroke in the blood pressure difference
trials, standardised to a blood pressure reduction of
10 mm Hg systolic and 5 mm Hg diastolic, together
with the corresponding relative risk estimates derived
from the meta-analysis of cohort studies (Prospective
Studies Collaboration analysis
25), in the age group
60-69 years, the average age at the time of a cardio-
vascular event in the trials (table 1). The estimates
from the trials meta-analysis were a 22% (95% confi-
dence interval 17% to 27%) reduction in CHD events
(relativerisk0.78)anda41%(33%to48%)reductionin
stroke (relative risk 0.59). The cohort study meta-ana-
lysis showed a 25% decrease in CHD events (relative
risk 0.75) and a 36% decrease in stroke (relative risk
0.64) for the same blood pressure difference of
10 mm Hg systolic, or 5 mm Hg diastolic (results
from other cohort study meta-analyses were
similar
2627). Thus the reductions in disease events in
the trials were similar to those expected from the
cohort study results for the same reduction in blood
pressure.
After only one year of follow-up (see web extra
table 1) the reduction in CHD events was 20% (9% to
29%)andthereductioninstrokewas32%(18%to44%)
fora reductionof 10mm Hgin systolicblood pressure
and 5 mm Hg diastolic, similar to the long term trial
results (22% and 41%) and similar to the results
expected from the cohort studies (25% and 36%; see
fig 2), indicating that the full potential effect of blood
pressure reduction is achieved within a year.
Figure 3 shows the reductions in CHD events and
stroke in the single drug trials comparing a specified
drug with placebo (or with a control group not receiv-
ing the study drug in nine trials), separately for each of
the five main classes of drug (the only drugs tested in
single drug trials). The five classes of drug produced
reductionsin CHDeventsandstrokethatwere similar
in magnitude. All the reductions were statistically sig-
nificant but for angiotensin receptor blockers there
were only four trials and hence insufficient statistical
power to show an effect. Average differences between
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Fig 7 | Reduction in incidence of coronary heart disease (CHD) events and stroke in relation to
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also reductions in disease incidence
Table 5 |Observed percentage reductions in coronary heart disease (CHD) events and stroke in single and combination drug treatment blood pressure
difference trials compared with predicted reductions according to number of drugs, dose, pretreatment blood pressure, and age (60-69 years) (tables 3 and
4), adjusted for proportion of treated participants not taking their allocated tablets (25%)
Category of
drug trial† Nooftrials*
Average No
ofdrugsper
participant
Mean dose
(multiple of
standard33)
Mean pretreatment
blood pressure
(mm Hg)
No of disease
events
Percentage reduction in cardiovascular disease events
CHD Stroke
Systolic Diastolic CHD Stroke
Observed
in trials
(95% CI)
Predicted
based on
systolic and
diastolic
Observed
in trials
(95% CI)
Predicted
based on
systolic and
diastolic
Single 65 1.0 1.7 140 81 9417 4712 15(11to19) 19 and 17 27(20to34) 25 and 25
Combination 8 2.0 1.2 160 91 394 708 25 (9 to 38) 36 and 34 41(31to50) 45 and 48
*One trial was part single drug and part combined drug therapy,
w118 hence numbers sum to 73 when there were 72 trials.
†In “single” drug trials the difference between intervention and control groups in average number of drugs taken per participant, taking account of “add-on” therapy in individual trials, was
<1.5, in combination drug trials ≥1.5.
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were small (0.03 drugs per participant) and similar for
the different classes of drug (see web extra figures 3a-i
forforestplotsoftheresultsofindividualtrialsforeach
classofdrug).Therewasnostatisticallysignificanthet-
erogeneity for CHD events across trials of the five
classesofdrug(χ
2=2.0,df=5,P=0.86),butthereduction
inincidenceofstrokewassmallerintrialsofβblockers
(17%) than in single drugtrials of the other four classes
of drug combined (29%; P=0.03).
Drug comparison trials
Figure4forCHDandwebfigures4a-eshowtheresults
of the drug comparison trials comparing each of the
five main classes of drug with drugs from the other
classes. The summary relative risk estimates for CHD
eventswerecloseto1.0,indicatingnoadvantageofany
one drug over others in the prevention of CHD. The
differences between classes of drug in average blood
pressure reductions were close to zero (fig 4), and the
differencesinuseofadd-ondrugswerenegligible(0.03
or fewer drugs per participant).The different classes of
drug therefore reduced blood pressure to about the
same extent and reduced CHD to about the same
extent, providing evidence of a lack of preventive
effects attributable to mechanismsother than lowering
blood pressure.
In the drug comparison trials the overall risk reduc-
tioninCHDeventswiththiazideswassimilartothatof
other classes of drug (fig 4). There was, however, an
increasedriskofsuddencardiac deathfromusingthia-
zides in very high dose, concealed in the summary
results because few of the thiazide trials used very
high doses and because sudden cardiac deaths were a
small proportion of all CHD events. In trials in which
thethiazidedosewashigh(≥4timesthestandarddose
33
) there were 33 sudden cardiac deaths in participants
allocated thiazides and 16 in those allocated other
drugs (with similar numbers of participants in each
group): relative risk 2.1 (P=0.01).
w125 w163 In trials
using doses between standard and twice standard, 57
and 40 sudden cardiac deaths occurred, respectively
(relative risk 1.4),
w15 w128 w130 w134 and in trials using
aroundhalfstandarddosetherewere16and19sudden
cardiacdeaths(relativerisk0.8;
w127 w131 w133;Pfortrend
0.058). These results indicate that higher doses of thia-
zides probably cause sudden death, and prospective
observational studies of people taking and not taking
thiazides show the same (attributable to lower serum
potassium levels causing ventricular arrhythmias).
34-41
Figure 4 for stroke and web extra figures 4f-j show
the corresponding drug comparison trial results on
stroke. The summary relative risk estimates for stroke
in the drug comparison trials were close to 1.0, with
two exceptions. Figure 4 suggests a greater preventive
effect of calcium channel blockers than other drugs,
andalessereffectofβblockers.Thegreaterpreventive
effect of calcium channel blockers (relative risk 0.91,
95% confidence interval 0.84 to 0.98; P=0.01) was not
materially altered after adjustment for the small differ-
ence in blood pressure reduction between the two
groups (relative risk 0.92, 0.85 to 0.98), and is equiva-
lent to a reduction in risk of stroke of 33% rather than
27%(theoverallsummaryestimate),since92%of0.73
(the average relative risk in the single drug trials, fig 3)
is0.67and1.0−0.67is0.33.Thelessereffectofβblock-
ersinpreventingstroke(fig4;relativerisk1.18,1.03to
1.36; P=0.02) was not materially altered by adjusting
for the small average difference in blood pressure
reduction between the randomised groups and is
equivalent to a 19% reduction in risk of stroke rather
than 27% (since 1.11×0.73 (average relative risk from
fig3)is0.81and1.00−0.81is0.19).Theobservedlesser
effect of β blockers, however, rested on trials compar-
ing calcium channel blockers with β blockers.
w136-w140
Exclusion of the results of these trials weakened the
evidence favouring a disadvantage of β blockers over
the three other classes (relative risk 1.11, 0.86 to 1.44;
P=0.40)buthad little effectonthe strengthof evidence
favouring an advantage of calcium channel blockers
over the three other classes of drug (relative risk 0.93,
0.86 to 1.01; P=0.07).
The drug comparison trial results in figure 4 were
similarandnotsignificantlydifferentwhensubdivided
into the three prespecified groups (no vascular disease
onentry(34trials),historyofCHD(10),andhistoryof
stroke (2)), but there were too few trial data to identify
any but quite large differences in this respect.
Should the use of blood pressure lowering drugs be limited
to people with “high” blood pressure?
TherelativeriskestimatesofCHDeventsandstrokein
the blood pressure difference trials were similar across
all levels of blood pressure before treatment down to
110 mm Hg systolic and 70 mm Hg diastolic, below
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Fig 6 | Reduction in incidence of coronary heart disease (CHD) events and stroke in relation to
reduction in diastolic blood pressure according to drug dose, number of drugs, pretreatment
diastolic blood pressure, and age. *Blood pressure reductions are more uncertain and hence
also reductions in disease incidence
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pressure level the relative risk reductions were statisti-
cally significant and consistent with the summary rela-
tive risk estimates for all the trials of 0.84 for CHD
events and 0.70 for stroke (table 2, also see web extra
figures 5a-l and 6a-m for forest plots of the individual
trialresults).Ameta-regressionanalysisshowednosig-
nificant trend in proportional disease reduction with
lower blood pressures before treatment indicating a
constant proportional effect. The trial results mirror
those in cohort studies,
25-27 which show a proportional
reduction in risk that is constant over all measured
levels of blood pressure—that is, the same in people
with lower and higher blood pressures.
There was no heterogeneity across the relative risk
estimatesforCHDaccordingtopretreatmentdiastolic
blood pressure (χ
2=3.9, df=6, P=0.69; fig 5). There was
heterogeneity for stroke (χ
2=19, df=6, P=0.004), owing
to a greater risk reduction in trials with the highest
blood pressure before treatment (≥95 mm Hg), which
arose because of more intensive treatment in these
trials (average difference between treated and placebo
groups of 1.7 blood pressure lowering drugs per parti-
cipant, compared with 1.0 drugs per participant in the
remaining trials with lower pretreatment blood pres-
sure). The same applied to the analysis based on systo-
lic blood pressure (CHD, χ
2=3.7, df=7, P=0.82 and
stroke χ
2=12.24, df=6, P=0.06; fig 5).
What is the quantitative effect of one or more blood
pressure lowering drugs in lowering blood pressure and in
preventing CHD events and stroke?
The effect of taking blood pressure lowering drugs in
reducing the incidence of CHD and stroke according
tonumberofdrugsused,doseofdrugs,andagecannot
be estimated from the blood pressure differences trials
alone. This is because a quarter of treated participants
stopped taking their allocated drugs, individual trials
used varying doses of drugs, trial data on combination
drug therapy were limited, and the age range was rela-
tivelynarrow.Allthiscanbeovercomebydoingatwo
stage analysis, which is set out in figure 6 (based on
diastolicbloodpressure)andfigure7(basedonsystolic
blood pressure). The first stage (upper portion of fig-
ures) was to estimate the effect of one drug at standard
dose in reducing blood pressure according to the level
of blood pressure before treatment, which was done
using results from a meta-analysis of short term (a few
weeks) placebo controlled trials of the drugs in fixed
dose.
32 Because of their short duration these trial
results have the advantage of not underestimating the
effectsofbloodpressurereductionthroughtreatedpar-
ticipants dropping out or controls receiving treatment.
The second stage (lower portion of figures) was to esti-
mate the effect of these blood pressure reductions in
preventing CHD and stroke. This was done using the
results of the meta-analysis of cohort studies,
25 rather
than those from our meta-analysis of the trial results,
becausethecohortstudiesquantifiedtheeffectsondis-
ease reduction across a wide range of blood pressure
reduction and age (which the trials cannot do), and the
evidence presented here shows that the cohort study
results reliably predict the results of randomised trials
over the ranges of age and blood pressure reduction
observedinthetrials,sovalidatingtheuseofthecohort
study data in this way.
Figures 6 and 7 show estimates of the effects of three
drugs in combination at half standard dose. Tables 3
and 4 show the estimates of the effects of one,two, and
three drugs at standard dose and one, two, and three
drugs at half standard dose in preventing CHD and
stroke according to pretreatment blood pressure and
age.
These estimates of the preventive effect of blood
pressure lowering drugs were calculated indepen-
dently of the trials of blood pressure lowering drugs,
so the trial results could be used to validate them.
Table 5 shows the predictions of the reductions in
CHD events and stroke in the blood pressure differ-
ence trials of single drug therapy (1.0 drug per partici-
pantonaverage)andofcombinationdrugtherapy(2.0
drugs per participant), calculated taking into account
blood pressure before treatment, dose as a multiple of
standard dose, and age and adjusted for the fact that a
quarterofparticipantsdidnottaketheirallocatedtreat-
ment. Table 5 shows that the observed reductions in
CHD events and stroke in the trials are similar to the
predicted values, so the trial results validate the esti-
mates.
Figures 6 and 7 show that one drug at standard dose
reduced the incidence of CHD by about 24% and of
stroke by 33% in people aged 60-69 with a systolic
blood pressure of 150 mm Hg and a diastolic blood
pressure of 90 mm Hg. Three drugs at half standard
dose about doubled this effect, reducing the incidence
Table 6 |Results on heart failure in 64 blood pressure difference trials and 31 drug
comparison trials of blood pressure lowering drugs, separately for calcium channel blockers
and other drugs
Class of drug No of trials No of episodes Relativerisk*(95%CI)
Blood pressure difference trials
Single drug therapy:
Calcium channel blockers 13 1519 0.81 (0.69 to 0.94)
Thiazides 5 222 0.59 (0.45 to 0.78)
β blockers 13 2846 0.77 (0.69 to 0.87)
Angiotensin converting enzyme inhibitors 16 3834 0.74 (0.68 to 0.81)
Angiotensin receptor blockers 3 1675 0.82 (0.73 to 0.92)
All drug classes except calcium channel
blockers
36† 8553† 0.76 (0.72 to 0.81)
Combination drug therapy 7 144 0.57 (0.36 to 0.92)
Drug comparison trials
Calcium channel blockers v any other drug class 21 4572 1.22 (1.10 to 1.35)
Drug comparisons not involving calcium channel
blockers:
Thiazides 2 2335 0.91 (0.64 to 1.30)
β blockers 2 335 1.04 (0.84 to 1.29)
Angiotensin converting enzyme inhibitors 9 5063 0.98 (0.91 to 1.06)
Angiotensin receptor blockers 7 2436 1.00 (0.93 to 1.08)
*Relative risk <1.0 indicates specified drug class reduces risk of heart failure; >1.0 increases risk.
†All trials totals are less than column totals because one trial had two treated groups sharing same placebo
group.
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blood pressure (180/105 mm Hg) and at lower blood
pressure(120/75mmHg)theeffectofonedrugatstan-
dard dose was about 7-9 percentagepointsgreater and
smaller, respectively, and of three drugs at half stan-
dard dose about 12-14 percentage points greater and
smaller. The proportional effect of age was relatively
small;inpeople10yearsoldertheeffectofonedrugat
standard dose was only 3 percentage points lower on
average,andofthreedrugsathalfstandarddose5per-
centage points lower. Because mortality from CHD
and stroke approximately trebles with each 10 year
increase in age, the absolute gain from blood pressure
reduction was greater at older ages.
If the drug treatment included a calcium channel
blocker, and the greater effect of calcium channel
blockers in preventing stroke (fig 4) was real and cau-
sal,therelativeriskestimatesforstrokeinfigures6and
7andintables3and4shouldbereducedby8%(multi-
plied by 0.92).
Heart failure
Table 6 shows the results on heart failure (17872 epi-
sodes), recorded in 64 blood pressure difference trials
and 31 drug comparison trials. Heterogeneity existed
within the results of the trials of β blockers and heart
failure (P=0.008), explained by the observation that β
blockerswithoutcardioselectiveorαblocking(vasodi-
latory) properties (propranolol, oxprenolol, pindolol,
and sotalol) lacked a preventive effect on heart failure
(relative risk 1.01, 95% confidence interval 0.76
to1.35), but β blockers with oneor other of theseprop-
erties hada preventiveeffect(relative risk0.77, 0.69 to
0.87;P=0.01fordifference).Datafromtrialsofthefirst
categoryofβblockers(seventrials,385episodes)were
therefore excluded from table 6.
Calcium channel blockers reduced heart failure in
the blood pressure difference trials by 19% (P=0.007),
although the drug comparison trials showed that they
were statistically significantly less effective in doing so
than the other four classes of drugs (relative risk 1.22,
1.10to1.35;P<0.001).Eachoftheotherfourclassesof
drug significantly reduced the incidence of heart fail-
ureinthebloodpressuredifferencetrials(P<0.001)by
24% on average, with no significant differences in
effectbetweenthemeitherinthebloodpressurediffer-
ence trials or the drug comparison trials. The effect of
calcium channel blockers in reducing heart failure in
thebloodpressuredifferencetrials(19%)wastherefore
not much less than that of the other classes of drug
(24%). The effect of the drugs was similar in primary
and secondary prevention (preventing new diagnoses
of heart failure and preventing deterioration (hospital
admission or death) in people with heart failure).
Non-vascular mortality and all cause mortality
In the blood pressure difference trials there was no
increase in cancer mortality (relative risk 0.96, 0.85 to
1.09) or in non-vascular mortality (relative risk 1.00,
0.94to1.06).Therewerestatisticallysignificantreduc-
tions in all cause mortality in all the blood pressure
difference trials (relative risk 0.87, 0.84 to 0.90;
P=0.001) and in trials of people with no vascular dis-
ease on entry (0.89, 0.84 to 0.95) and with a history of
CHD(0.86,0.81to0.90)andstroke(0.91,0.83to1.01).
DISCUSSION
This, the largest meta-analysis of randomised trials of
blood pressure reduction to date, shows that lowering
systolicbloodpressureby10mmHgordiastolicblood
pressure by 5 mm Hg using any of the main classes of
blood pressure lowering drugs, reduces CHD events
(fatal and non-fatal) by about a quarter and stroke by
about a third, regardless of the presence or absence of
vascular disease and of blood pressure before treat-
ment, with no increase in non-vascular mortality.
Heart failure is also reduced by about a quarter.
β blockers in people with CHD
Our results confirm that there is a special protective
effect of β blockers in preventing CHD events in peo-
plewithaclinicalhistoryofCHDoverandabovetheir
blood pressure lowering effect. This special effect was
limited to a few years after an acute myocardial
Table 7 |Source of evidence from three large meta-analyses
Drug effects
Meta-analysis of cohort
studies of blood pressure
and risk of CHD and stroke
(2002)25
Meta-analysis of trials of
drugsbyclassanddoseand
blood pressure reduction
(2003)32
Meta-analysis of “event”
trials of drugs by class and
reduction in CHD andstroke
(present analysis)
Comment on evidence
from event trials
(present analysis)
Effect of drug on blood pressure according to:
Class of drug Uninformative Informative Uninformative Estimatesdilutedbecause24%ofparticipants
stopped taking tablets
Dose of drug Uninformative Informative Uninformative Differentparticipantstookdifferentdoses;low
dose not tested
No of drugs Uninformative Informative Uninformative Statistical power too low
Effect of blood pressure reduction on disease
according to:
Pretreatment blood pressure Informative Uninformative Informative Significantreductionindiseaseeventsevenat
lowest blood pressure
Class of drug Uninformative Uninformative Informative Extensive
Age Informative Uninformative Uninformative One narrow age range (60-69 years)
CHD=coronary heart disease.
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ble that ofβ blockersin people withclinical CHD with
no recent infarct or without CHD and that of other
drugs regardless of history of CHD. This analysis and
the consequent conclusion was possible because the
trialsinwhichparticipantswererecruitedimmediately
after an acute infarct had relatively short durations of
follow-up (typically one or two years). The fortuitous
dichotomy of the trial data on β blockers in CHD into
short term trials in acute infarction and trials of non-
acute CHD provided the opportunity to show that
the special effect of β blockers was a short term effect,
avoiding the dilution of effect that would have
occurred had the acute infarct trials continued for
many years after the infarct. The results confirm a sug-
gestion made over 25 years ago from a non-significant
difference between short term and long term preven-
tion observed in one trial.
w62
Preventive effect in people with and without cardiovascular
disease
With the exception of the special short term effect of β
blockers in acute myocardial infarction, our results
show that the preventive effect of all classes of blood
pressure lowering drugs is the same or similar in peo-
plewithandwithoutahistoryofcardiovasculardisease
(table 2), so there is no reason to use these drugs for
secondary prevention but not for primary prevention.
The trial results after one year of follow-up show that
the preventive effect of blood pressure reduction is
rapid, the full potential effect being achieved within a
year,aresultthatdiffersfromserumcholesterolreduc-
tion, which has little effect in the first year.
42
Quantitative linking of blood pressure reduction and
disease prevention
An important result from our analysis is that results
fromthe meta-analysisof trialsofdrugsonbloodpres-
surereductionlinkedtothecohortstudiesmeta-analy-
sis (differences in risk of CHD events and stroke for
specifieddifferencesinbloodpressure)accuratelypre-
dict the results of the present trials meta-analysis, indi-
cating that blood pressure reduction in itself explains
the preventive effect of the drugs. With the possible
minor additional effect of calcium channel blockers
in preventing stroke the five classes of drugs were
equally effective in lowering blood pressure (confirm-
ing previous work
32) and equally effective in prevent-
ing CHD events and stroke (figs 3 and 4). A possible
explanation for the greater effect of calcium channel
blockers on the risk of stroke
3-791043 is the observation
that although the different classes of blood pressure
lowering drugs reduce peripheral arterial pressure to
a similar extent,
32 the reduction in central aortic pres-
sure appears greater with calcium channel blockers
and lower with β blockers than with the other three
classes of drug.
44-46 But it is not a persuasive argument
becauseanyadditionalreductionincentralaorticpres-
sure should also confer greater prevention against
CHD than with other drugs but this was not observed
(figs 3 and 4). Thus with the exception of β blockers
after acute myocardial infarction and the minor addi-
tional effect of calcium channel blockers in reducing
the risk of stroke, blood pressure reduction explains
the action of the drugs in preventing CHD and stroke;
the results thus exclude the blood pressure lowering
drugs in general having material pleiotropic effects.
The assessment of β blockers as inferior drugs for
lowering blood pressure
14-18 was based on fewer trials
than were considered here; they had a similar protec-
tive effect on CHD to other drugs (fig 3) and a greater
protectiveeffectaftermyocardialinfarction(fig1),sup-
porting guidelines that do not discourage their use.
24
Our results did not corroborate the suggested stronger
protective effect of angiotensin converting enzyme
inhibitors or weaker protective effect of angiotensin
receptor blockers or calcium channel blockers against
CHD.
18131920w155
Although our results do not exclude possible differ-
ences in efficacy between drugs within a class this is
unlikely. Any such differences are likely to be small
andclinicallyunimportant,however,because(βblock-
ers and heart failure apart) for each class of drug there
was no significant heterogeneity between trials of the
individual drugs studied, either for blood pressure
reduction
32 or for reduction in disease events (see
web extra table A). Trial results that suggest greater
or lesser effects of some drugs can be explained by
chance alone. One drug, atenolol, has been thought
tobeinferiortootherβblockers,
1415butasfarasstroke
preventionisconcernedthisresultisprobablysecond-
ary to the greater effect of calcium channel blockers in
drugcomparisontrials.AsfaraspreventionofCHDis
concernedthiswasduetopreviousmeta-analyseslack-
ing statistical power. The relative risk estimate from a
previous analysis of four blood pressure difference
trials of atenolol of 0.99 (95% confidence interval
0.83 to 1.19)
15 was revised to 0.93 (0.75 to 1.14) in
ouranalysiswiththeinclusionoftwoadditionalateno-
lol trials,
w64 w66 and both relative risk estimates are
strongly influenced by the result of one trial, which
implausibly suggests no effect at all (relative risk 1.01,
0.78 to 1.31
w14). Without this one trial the relative risk
estimate is 0.86 (0.64 to 1.16), close to the estimate of
What is already known on this topic
The different classes of blood pressure lowering drugs at standard doses, or the same
multiple of standard dose, lower blood pressure to a similar extent
Blood pressure lowering drugs reduce the risk of coronary heart disease (CHD) events and
stroke in people with a history of vascular disease and in those with high blood pressure
What this study adds
The effect of blood pressure lowering drugs in reducing the risk of disease is entirely or
largely due to blood pressure reduction, with one main exception, a special extra effect of
β blockers in people who have had a recent myocardial infarction
The proportional reduction in CHD events and stroke for a given reduction in blood
pressure, an approximate halving in risk for each 10 mm Hg diastolic reduction, is the
same in people with and without a history of vascular disease and in people without high
blood pressure as well as in those with high blood pressure
There is benefit in lowering blood pressure in anyone at sufficient cardiovascular risk
whatever their blood pressure, so avoiding the need to measure blood pressure routinely
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able evidence, there is no reason to conclude that β
blockers in general, or atenolol in particular, are less
effective than other blood pressure lowering drugs.
In most of the blood pressure difference trials blood
pressure was not monitored, but in about a third of
these trials there was a treat to target policy applied to
the treated groups. This was possible in double blind
trials because the dispenser but not the investigator
knew the allocated regimen and increased the dose of
either the drug or the placebo as appropriate. In these
trialstheuseofadd-ontreatmentwasthesameonaver-
age in the treated and placebo groups (overall differ-
ence 0.3drugsperparticipant).Over allthe trials,25%
of participants allocated active treatment stopped tak-
ing their tablets; this non-adherence did not bias com-
parisons between the classes of drug because the
proportions who stopped were similar for each class.
Thenon-adherence underestimatesthe effectoftaking
the drugs on disease prevention but does not underes-
timatetheeffectofaspecifiedbloodpressurereduction
from the drugs on disease prevention because the cal-
culation of the difference in blood pressure took non-
adherence into account. Thus the observations that a
blood pressure reduction of 10 mm Hg systolic or
5 mm Hg diastolic, however achieved, reduced CHD
events by 22% and stroke by 41% in the trials are
unbiased estimates of efficacy.
A treat to target policy for lowering blood pressure
was applied in most of the drug comparison trials; this
was, from a scientific perspective, an advantage
because it helped ensure that the differences in blood
pressure between the arms of the trial were minimal
(fig 3). The differences in use of additional drugs
between the randomised groups were small (0.3
drugs per participant or fewer in trials comparing
each class of drug with any other drug). The observa-
tion that there were no material differences in blood
pressure between the groups and no material differ-
ence in the incidence of CHD or stroke (fig 4) permits
the conclusion that the preventive effects of each class
ofdrugaremediatedthroughbloodpressurereduction
alone, corroborating the conclusion that the drugs did
not have pleiotropic effects based on the similarity in
predicted and observed results from the drug differ-
ence trials (fig 2).
Proportional disease reduction for a given blood pressure
reduction independent of pretreatment blood pressure
Ourresultsindicatethatthe useofbloodpressurelow-
ering drugs should not be limited to people with high
blood pressure. The proportional reduction in disease
events for a given blood pressure reduction was the
same irrespective of blood pressure before treatment
(fig 5), down to levels of 70 mm Hg (or lower) for dia-
stolic blood pressure, as expected from the results of
epidemiological cohort studies that showed a constant
proportional change in risk for a specified change in
bloodpressurefromanylevelofbloodpressurebefore
treatment.
25-27 This result, and the previously pub-
lished trials showing a greater risk reduction for a
greater blood pressure reduction,
4-6 support a “lower
the better” approach to blood pressure reduction. It
means that there is medical benefit in lowering a per-
son’sbloodpressurewhateverthebloodpressure,with
the logically inescapable conclusion that there is then
little or no gain in routinely measuring a person’s
blood pressure—a conclusion that will undoubtedly
stimulate discussion since it is at variance with
100 years of medical practice.
Ourestimatesoftheproportionalreductioninriskof
CHD events and stroke vary according to age (figs 6
and 7 and tables 3 and 4). In a recent meta-analysis of
31trials,
47usingindividualpatientdataorunpublished
tabulardatainprespecifiedcategories,theauthorscon-
cluded that age had no material influence on attenuat-
ingtheeffectofbloodpressurereductioninpreventing
cardiovascular disease. However, their results did
show an attenuating effect of age; the risk of cardio-
vascular disease was reduced by 24% per 5 mm Hg
reduction in systolic blood pressure for a 15 year
increase in age (11.9% cardiovascular disease preven-
tionreducedto9.1%),althoughthiswasnotstatistically
significant.
43 This estimate was close to the 20%
expected decrease from the results of the cohort
study meta-analysis we used.
25 The 24% estimate
from the trial meta-analysis was probably real but was
not statistically significant because the blood pressure
reductions observed in the trial were relatively small
and the reductions in cardiovascular disease were
therefore also small. The important conclusion is that
the cohort studies and the trial data are entirely
Summary of answers to questions posed
 Do β blockers have a special effect in preventing CHD events in people with a clinical
history of CHD?
 Yes. The effect is an approximate 30% reduction in CHD, present for a few years after
the infarct. This risk reduction is about 15% thereafter, similar to that of other blood
pressure lowering drugs
 Does the preventive effect of drugs differ in people with and without a history of
cardiovascular disease?
 No. The percentage reduction in risk of CHD events and stroke is the same or similar.
Since the absolute risk is higher in people with a history of cardiovascular disease,
however, the absolute risk reduction is greater
 Does blood pressure reduction alone explain the preventive effect of the drugs?
 Yes, except for the special short term effect of β blockers
 Should theuse of blood pressure lowering drugs be limited to peoplewith “high”blood
pressure?
 No.Bloodpressureloweringdrugsshouldbeofferedto anyonewithahighenoughrisk
to benefit from treatment whatever their reason for being at high risk, because a given
blood pressure reduction lowers risk of CHD and stroke by a constant proportion
irrespective of pretreatment blood pressure
 W h a ti st h eq u a n t i t a t i v ee f f e c to ft a k i n go n eo rm o r eb l o o dp r e s s u r el o w e r i n gd r u g so n
blood pressure and the risk of CHD events and stroke?
 In people aged 60-69 with a diastolic blood pressure of 90 mm Hg (or systolic blood
pressure of 150 mm Hg): one drug at standard dose lowers the risk of CHD by about
25% and of stroke by 35%; three drugs at half standard dose lower the risk of CHD by
45% and of stroke by 60%; the estimates are about 10 percentage points higher if
bloodpressureishigherby30mmHgsystolicor15mmHgdiastolic;theestimatesare
about 5 percentage points lower for a 10 year increase in age
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ventionofCHDeventsandstrokeinrelationtoreduc-
tions in blood pressure.
From drugs to blood pressure reduction to disease
prevention: a quantitative summary
Figures 6 and 7 provide an overall quantitative sum-
mary of the effect of blood pressure reducing drugs
on blood pressure reduction according to blood pres-
sure levels before treatment, dose of drugs, and num-
berofdrugs,andthecorrespondingreductioninCHD
events and stroke according to age, derived from
cohort studies, showing a reduced proportional effect
with increasing age. The analysis of the randomised
trials of blood pressure reduction presented here was
notusedtoderivetheestimatesbutprovidesimportant
confirmation of them,both by showing that the cohort
studies (on which these estimates were based) reliably
predictthereductioninCHDeventsandstrokereduc-
tion in the randomised trials for the same difference in
blood pressure (fig 2), and by showing that the esti-
mates reliably predict the CHD events and stroke in
the randomised trials according to number and dose
of drugs without directly taking the blood pressure
reduction into account (table 5). The estimates are
therefore validated in that they predict trial data over
the ranges of age and blood pressure reduction avail-
able in trials.
Tables 3 and 4 present a numerical expansion of fig-
ures 6 and 7. These results answer our fifth question,
which enables a doctor prescribing blood pressure
lowering treatment to know by how much that treat-
ment is expected to reduce an individual’s risk of
stroke and CHD in relation to the number and dose
of drugs used, blood pressure level before treatment,
and age. Meta-analyses of trials on disease events can-
not, on their own, answer such questions. A synthesis
of data from different sources, observational and
experimental,isneeded.Table7showshowthediffer-
ent pieces of the puzzle come from three large meta-
analyses, the last one being the present study. Only
suchan integrative approachprovidesthe quantitative
summary set out in figures 6 and 7, which answers our
fifth question.
Assessing the need to tailor treatment
Inclinicalpracticeattentionisoftenplacedontailoring
blood pressure drug treatment to individual patients,
on the basis of factors such as comorbidities, adverse
effects, and cost.
2324
Comorbidities
The results of this analysis and of other studies on
comorbidities indicate that the claimed advantages of
one drug over another for an individual who has an
existing disease are generally of minor importance.
Our results show that all classes of drug are effective
in heart failure (non-cardioselective β blockers apart)
and after myocardial infarction (the greater effect of β
blockers apart). Calcium channel blockers seem to be
less effective than other drugs in heart failure but the
difference in risk reduction is not large (19% v 24%;
table 6) and they are no less effective after myocardial
infarction. All classes of drug prevent headaches and
migraine,
48-50althoughcalciumchannelblockersdoso
onlyinlow(halfstandard)dose.
51Thereisnoevidence
to support recommendations for particular classes of
drug in older or younger people.
47 A relative contra-
indication of even cardioselective β blockers in people
with airways obstruction or peripheral arterial disease
is perceived,
24 but a meta-analysis of trials has shown
that cardioselective β blockers donot produce adverse
respiratory effects in mild to moderate obstructive air-
ways disease
52; such considerations are not a reason to
withhold a β blocker, but reinforce the principle that
patients should be monitored for side effects of drugs
and a drug should be withdrawn if it causes adverse
effects. Most of the classes of drug have advantages in
preventing non-vascular diseases. Thiazides prevent
renal calculi
w164 and may prevent hip fracture (they
increase bone density in randomised trials and are
associated with a reduced risk of hip fracture in pro-
spective observational studies
53-55). β blockers are
advantageous in glaucoma.
24 Angiotensin converting
enzyme inhibitors and angiotensin receptor blockers
reduce the incidence of diabetes and diabetic and
non-diabeticnephropathy.
24Usingthedrugsincombi-
nation rather than singly therefore offers several med-
ical benefits.
Adverse effects
Adverse effects are also a reason for seeking to indivi-
dualise treatment. Tolerability, however, is minimised
by using low dose combination therapy, as the preva-
lence of symptoms for three of the classes of drug is
strongly related to dose,
32 and low dose combination
therapy can greatly improve safety. For example, the
risk of sudden cardiac death was avoided using thia-
zides in low dose in the trials, probably because thia-
zides cause little reduction in serum potassium at half
standard dose,
3233 and using thiazides in combination
with angiotensin converting enzyme inhibitors or
angiotensin receptor blockers, which increase serum
potassium levels, counters the potential hazard.
3256
The diabetogenic effect of thiazides is strongly related
to dose, and minor at low dose (the increase in blood
glucose is 1% at half standard dose, 3% at standard
dose, and 5% at twice standard dose
32), and the effect
is offset by angiotensin converting enzyme inhibitors
and angiotensin receptor blockers.
2456 Thiazides may
cause gout, but again the increase in serum uric acid is
attenuatedat low dose
3233 and opposedby angiotensin
converting enzyme inhibitors and angiotensin recep-
tor blockers.
w165-w167 Angiotensin converting enzyme
inhibitors and angiotensin receptor blockers are tera-
togenicandshouldbeavoidedinpregnancy.
5758Aran-
domised trial carried out to assess the effects of blood
pressure lowering drugs on sexual function confirmed
the recognised effects of thiazides but showed that
other classes of blood pressure lowering drug (includ-
ing β blockers) did not differ from placebo.
59
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Costisanotherreasonforselectingparticularclassesof
drug but has become a minor consideration because
suitable off-patent blood pressure lowering drugs in
four of the five classes are available at low cost, and
will be available for the fifth (angiotensin receptor
blockers) later in 2009.
It is difficult to defend the widespread practice of
tailoring treatment. The case for individualising
blood pressure lowering therapy disappears with low
dose combination therapy based on three drugs; the
greaterefficacycomparedwithselectivemonotherapy
or dual therapy avoids the need to choose between
drugs.
Strengths and limitations of the study
Potential limitations of this meta-analysis arise from
not having individual patient data from the individual
trials. While this would have provided more detail on
the effects of blood pressure reduction in relation to
pretreatment blood pressure and age it was not a ser-
ious limitation. The trials varied sufficiently for pre-
treatment blood pressure to be informative, so this
was not a serious limitation. With regard to age, the
observation that in the age group covered by the trials
asawhole(60-69)theresultswereasexpectedfromthe
cohort studies indicates that the synthesis of these two
sourcesofdata overcomesthislimitationfromthe trial
meta-analysis. The fact that our meta-analysis was
based on trials that varied in many ways (for example,
with respect to pretreatment blood pressure, previous
disease, population sample) may be thought to be a
limitation,possiblyleadingtorandomerror obscuring
real differences. This was not the case, however; the
meta-analysis was sensitive enough to show that the
trial results were as expected from cohort studies and
it is therefore unlikely that random error or bias could
haveproducedourresults.Itisalsoextremelyunlikely
that random or systematic error in the analysis would
produce essentially identical quantitative results when
dichotomisedindifferentways,suchaswithorwithout
cardiovascular disease. Indeed, the consistency of our
results in the face of such variable trial designs rein-
forces, not diminishes the validity of the conclusions.
There are sparse direct data to show an additive effect
of different combinations of three blood pressure low-
ering drugs on blood pressure, but it is reasonable to
conclude that combinations of three are additive since
this is true for combinations of two drugs,
3260 and the
estimatesoftheefficacyofthreedrugsshowninfigures
7and8andintables3and4arebasedonthisinference.
Thestrengthofouranalysesisthat,basedastheyare
onrelativereductionsinrisk,theyaregenerallyapplic-
ableirrespectiveoftheincidenceofcardiovasculardis-
ease. However the preventive potential needs to be
assessed in terms of the absolute risk reduction. Our
estimates of relative risk reduction may be converted
to absolute risk reductions by multiplying them by the
incidenceinaspecifiedpopulation.Forexampleatage
65 the 10 year risk of myocardial infarction (fatal or
non-fatal) in England and Wales was estimated as
being about 10% in men and 5% in women.
33 Given
an average blood pressure at that age of 150 mm Hg
systolicand90mmHgdiastolic
33theexpectedrelative
riskreductionusingthreedrugsathalfstandarddoseis
46%(tables3and4),sotheabsoluteriskreductionover
10 years in men is 4.6% (from 10% to 5.4%) and in
women is 2.3% (from 5% to 2.7%). The corresponding
absolute risk reduction for stroke is 2.9% in men and
2.3% in women, based on 10 year incidences of 5% in
men and 4% in women.
33 For myocardial infarction
and stroke combined, therefore, the absolute risk
reduction in men is 7.5% and in women is 4.6%.
Demonstratingthevalueofbloodpressurelowering
treatmenttoeveryoneina populationaboveaparticu-
lar age might be perceived as “medicalising” a popula-
tion. We disagree with this view. Identifying people
with a relatively high blood pressure for their age, giv-
ing them the medical diagnosis “hypertension,” and
treating this “disease” clearly medicalises the indivi-
duals concerned. Offering blood pressure lowering
treatmentsto apopulationabovea certainage,regard-
less of their blood pressure, on the basis that it would
prevent a future heart attack and stroke with minimal
adverse effects, in our view does not medicalise the
population, unless the broad view is taken that anyone
who takes a preventive agent regularly is medicalised.
Such a broad view would mean that people receiving
antimalarials, vaccines, or contraceptive pills are med-
icalised, which few would judge to be the case.
We conclude our analysis by summarising our
answers to the five questions we initially posed (box).
The preventive effect of lowering blood pressure is
substantial and capable of reducing the incidence of
CHD and stroke by at least half in all people at risk of
CHD events or stroke whatever their blood pressure
and whatever the basis of being at risk—for example,
having had a cardiovascular disease event or simply
being older. Our results support the view that blood
pressure lowering drugs should no longer be regarded
as treatment for hypertension in the same way that sta-
tins are now no longer regarded as treatment for
hypercholesterolaemia. Consideration should be
given to replacing current policies that focus on routi-
nely measuring blood pressure with policies that focus
on routinely lowering blood pressure.
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